Description
BPS Bioscience has developed a diverse portfolio of lentivirus products to study COVID-19, cell signaling pathways, CAR T-cell therapy, CRISPR, and immunotherapy. In addition to our product portfolio, we also offer custom services to develop a lentivirus suited for your research needs.
Customizable Options: - Reporters (GFP, Luciferase, Dual Reporter)
- Antibiotic selection markers (Puromycin, Hygromycin, G418)
- Integrating or non integrating
- Pseudotyped
- CRISPR lentiviruses
- CRISPR activation lentiviruses